Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessCompanies

EXCLUSIVE: Bangladesh drugmakers signed up by Maharashtra govt don't have licence to sell remdesivir in India

CDSCO hasn't received application from any Bangladesh companies for remdesivir import licence.

June 09, 2020 / 08:09 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

The two Bangladesh drug makers, Eskayef Pharmaceuticals and Bexmico Pharma, that have offered to supply remdesivir to the Maharashtra government, haven't yet approached the Indian drug regulator, sources in the Central Drugs Standard Control Organisation (CDSCO) told Moneycontrol.

"We haven't received remdesivir applications from any Bangladesh companies seeking import licence. The companies that said to have offered to supply the drug to the Maharashtra government are unregistered," said an official, who didn't want to be named.

"Currently, we are reviewing the application of Indian drug makers; that's taking some time," the official added.

On June 6, Rajesh Tope, Maharashtra Health Minister, said the state would buy remdesivir from Dhaka-based Eskayef Pharma for Rs 12,000 per vial for 10,000 doses.

Mumbai Mirror reported that another company, Beximco, offered to sell at $65 per vial (Rs 5,000).

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Maharashtra's announcement came even as three Indian companies - Cipla, Hetero and Jubilant Life Sciences - are awaiting marketing authorisation approvals from the Indian drug regulator. The three companies have licences from Gilead to produce and distribute the drug in 127 low and middle-income countries (LMICS).

Gilead earlier told Moneycontrol it has not provided a licence to Eskayef Pharmaceuticals or any other company in Bangladesh to manufacture remdesivir.

"Gilead cannot comment on or verify the authenticity or effectiveness of this product as it is not manufactured by Gilead or one of our licensed partners," it said.

Viswanath Pilla
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jun 9, 2020 07:25 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347